I will say that the possibility of stopping a PIII study at say interim analysis would be more likely because of the larger patient pool. However this is still speculating until it happens. We must remember too that in order for sales reps to market the drug efficiently data is needed to show the prescribing physician. Sales professionals need all the info they can get.... This is coming from a Biotech Sales rep ;)
Market Data 
Markets 
AI
